Baiyao Technology
百曜科技
Baiyao Technology is an AI virtual cell (AIVC) platform company founded in 2023 that builds foundational large models to simulate and predict cellular behavior under different interventions—such as drugs, gene editing, and environmental changes—using massive single-cell multi-omics datasets . In June 2025, it raised a new funding round of tens of millions of RMB, with participation from the Yunqi-SJTU AI Angel Fund, a vehicle operated by Yunqi Capital . The company positions its technology as a new underlying tool for drug R&D, cell therapy, and disease research, aiming to bring life-system changes into what it calls the "computable era" .
AI-generated — may contain errors, please verify.
Coverage
Has the Inflection Point for AI for Science Arrived?
Where will the next Nobel Prize emerge?
峰瑞资本·Yunqi Capital Invests in Baiyao Technology: AI Virtual Cells Bring Life System Changes into the Computable Era | Yunqi Partners
State Investment Funds Enter the Arena, Opening a New Dimension in Life Science Computing
云启资本·Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
峰瑞资本·From Two Rounds in Six Months to a $400M Series D: 10 Companies Announce New Funding | FreeS Family Funding News Vol.24
Looking forward to working alongside more outstanding founders.
峰瑞资本·
